---
title: "Ibritumomab Tiuxetan - Follicular Non-Hodgkin'S Lymphoma"
sidebar: mydoc_sidebar
permalink: db00078-mesh-d008224-1.html
toc: false 
---


Path ID: `DB00078_MESH_D008224_1`
{% include image.html url="images/db00078-mesh-d008224-1.png" file="db00078-mesh-d008224-1.png" alt="db00078-mesh-d008224-1" %}

## Concepts

|------------|------|---------|
| Identifier | Name | Type    |
|------------|------|---------|
| <a href="https://identifiers.org/MESH:C422802">MESH:C422802 </a> | ibritumomab tiuxetan | Drug |
| <a href="https://identifiers.org/UniProt:P11836">UniProt:P11836 </a> | B-lymphocyte antigen CD20 | Protein |
| <a href="https://identifiers.org/GO:0006959">GO:0006959 </a> | humoral immune response | BiologicalProcess |
| <a href="https://identifiers.org/MESH:D015021">MESH:D015021 </a> | Yttrium Radioisotopes | ChemicalSubstance |
| <a href="https://identifiers.org/MESH:D001610">MESH:D001610 </a> | beta particles | ChemicalSubstance |
| <a href="https://identifiers.org/GO:0001788">GO:0001788 </a> | antibody-dependent cellular cytotoxicity | BiologicalProcess |
| <a href="https://identifiers.org/GO:0097278">GO:0097278 </a> | complement-dependent cytotoxicity | BiologicalProcess |
| <a href="https://identifiers.org/GO:0008219">GO:0008219 </a> | Cell death | BiologicalProcess |
| <a href="https://identifiers.org/CL:0001063">CL:0001063 </a> | tumor cell | Cell |
| <a href="https://identifiers.org/MESH:D008224">MESH:D008224 </a> | Follicular non-Hodgkin's lymphoma | Disease |
|------------|------|---------|

## Relationships


NOTE: predicates are annotated in <a href="https://github.com/biolink/biolink-model/releases/tag/v1.3.0">Biolink Model (v1.3.0)</a>

|---------|-----------|---------|
| Subject | Predicate | Object  |
|---------|-----------|---------|
| Ibritumomab Tiuxetan | PHYSICALLY INTERACTS WITH | B-Lymphocyte Antigen Cd20 |
| B-Lymphocyte Antigen Cd20 | POSITIVELY REGULATES | Humoral Immune Response |
| Ibritumomab Tiuxetan | COEXISTS WITH | Yttrium Radioisotopes |
| Yttrium Radioisotopes | PRODUCES | Beta Particles |
| Beta Particles | CAUSES | Cell Death |
| Humoral Immune Response | POSITIVELY REGULATES | Antibody-Dependent Cellular Cytotoxicity |
| Humoral Immune Response | POSITIVELY REGULATES | Complement-Dependent Cytotoxicity |
| Complement-Dependent Cytotoxicity | PRECEDES | Cell Death |
| Antibody-Dependent Cellular Cytotoxicity | PRECEDES | Cell Death |
| Cell Death | DECREASES ABUNDANCE OF | Tumor Cell |
| Tumor Cell | MANIFESTATION OF | Follicular Non-Hodgkin'S Lymphoma |
|---------|-----------|---------|

Comment: Ibritumomab tiuxetan is an Indium or yttrium conjugated murine IgG1 kappa monoclonal antibody directed against the CD20 antigen, The Fab segment of the antibody targets the CD20 epitope on B-cells, allowing the radioactive yttrium to destroy the cell via production of beta particles.

Reference: 
  - [https://go.drugbank.com/drugs/DB00078](https://go.drugbank.com/drugs/DB00078)
  - [https://en.wikipedia.org/wiki/Ibritumomab_tiuxetan](https://en.wikipedia.org/wiki/Ibritumomab_tiuxetan)
  - [https://en.wikipedia.org/wiki/Antibody-dependent_cellular_cytotoxicity](https://en.wikipedia.org/wiki/Antibody-dependent_cellular_cytotoxicity)
